Cart
sales@molnova.com
HPK1-IN-2
CAS No. 2056122-11-1
HPK1-IN-2( Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2 )
Catalog No. M23923 CAS No. 2056122-11-1
HPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 219 | In Stock |
|
| 10MG | 365 | In Stock |
|
| 25MG | 608 | In Stock |
|
| 50MG | 866 | In Stock |
|
| 100MG | 1152 | In Stock |
|
| 500MG | 2331 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHPK1-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionHPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ).
-
DescriptionHPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ). It also inhibits Lck (0.05 μΜIn Vitro——In Vivo——SynonymsThieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2PathwayAngiogenesisTargetFLTRecptorFlt3|HPK1|LckResearch Area——Indication——
Chemical Information
-
CAS Number2056122-11-1
-
Formula Weight380.47
-
Molecular FormulaC19H20N6OS
-
Purity>98% (HPLC)
-
SolubilityH2O:25 mg/mL?(55.14 mM;?Need ultrasonic)
-
SMILESO=C1C(C2=NC3=CC=C(N4CCN(C)CC4)C=C3N2)=C(N)C(C=CS5)=C5N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Peter Brent Sampson, et al. Hpk1 inhibitors and methods of using same. WO2016205942A1.
molnova catalog
related products
-
AXL-IN-13
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.
-
BGB-102
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
-
Gilteritinib hemifum...
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
